Drug intelligence / Profile preview

AGX-405

Development stage: Unknown
Lead developer: AgonOx
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AGX-405 is an investigational enhanced tumor-infiltrating lymphocyte (TIL) therapy developed by AgonOx for the treatment of cancer. The drug acts as a modulator of the T-cell surface antigen CD4, aiming to enhance anti-tumor immune responses by targeting and modulating CD4-positive T cells within tumors. As of the latest updates, its highest development status is at the Discovery phase and it has not yet entered clinical trials or received regulatory approval[1][2].

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on AGX-405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX-405.

Explore the full profile